Murray M
Department of Medicine, University of Sydney, Westmead Hospital, NSW, Australia.
Mol Pharmacol. 1992 Nov;42(5):931-8.
Antidepressant drugs that contain alkylaminoalkyl substituents have been associated with serious pharmacokinetic interactions in humans that may be related to the inhibition of cytochrome P450 (P450) enzymes. In this study, the propensity of the tricyclic antidepressant nortriptyline (NOR) to inhibit individual microsomal P450 enzymes in rat liver was investigated to provide a mechanistic explanation for these pharmacokinetic interactions. Enzyme kinetic studies revealed that NOR inhibited steroid 2 alpha-, 6 beta, 7 alpha-, and 16 alpha-hydroxylation in untreated rat liver with Km/Ki ratios of 0.53, 0.59, 0.25, and 0.29, respectively. When the drug was preincubated with microsomes and NADPH before testosterone hydroxylation was conducted, marked increases in the Km/Ki ratios were observed (to 8.8, 3.9, 0.62, and 13, respectively). Thus, enzymic oxidation of NOR enhanced its inhibition capacity against P450 activities. Indeed, the altered Km/Ki ratios indicate 17-, 6.6-, 2.5-, and 47-fold increases in inhibition of the four pathways of testosterone hydroxylation after the biotransformation of NOR to its metabolites. From these experiments it was apparent that testosterone 2 alpha- and 16 alpha-hydroxylations, catalyzed predominantly by P450 2C11, were subject to the most pronounced increase in inhibition. Under these conditions, the apparent content of microsomal P450 was decreased, thus suggesting the formation of a NOR metabolite intermediate (MI) complex with the cytochrome. Further, optical difference spectroscopy of NADPH-supported metabolism of NOR in microsomes and in a reconstituted system incorporating purified P450 2C11 indicated the appearance of an absorbance peak near 454 nm, similar to those produced by triacetyloleandomycin, SKF 525-A, and orphenadrine. Formation of this absorbance peak in microsomes was inhibited by an antibody raised against the male-specific P450 2C11. Because oxidative metabolism of NOR to inhibitory products would not necessarily involve MI complexation, additional experiments were undertaken in which NOR-related free metabolites produced in microsomal incubations were removed on Sep-Pak mini-C18 columns before estimation of testosterone hydroxylation. The principal finding from this experiment was that P450 3A2-dependent steroid 6 beta-hydroxylase activity was inhibited to a much lesser extent after removal of unbound NOR metabolites on Sep-Pak columns (25% inhibition after Sep-Pak extraction, compared with 82% inhibition observed when all NOR metabolites were present during subsequent testosterone hydroxylation); inhibition of P450 2C11-mediated 2 alpha- and 16 alpha-hydroxylation was not noticeably different after Sep-Pak treatment.(ABSTRACT TRUNCATED AT 400 WORDS)
含有烷基氨基烷基取代基的抗抑郁药物已被证实与人类严重的药代动力学相互作用有关,这可能与细胞色素P450(P450)酶的抑制作用有关。在本研究中,研究了三环类抗抑郁药去甲替林(NOR)抑制大鼠肝脏中单个微粒体P450酶的倾向,以对这些药代动力学相互作用提供一个机制性解释。酶动力学研究表明,NOR抑制未处理大鼠肝脏中的类固醇2α-、6β、7α-和16α-羟基化,其Km/Ki比值分别为0.53、0.59、0.25和0.29。当在进行睾酮羟基化之前将该药物与微粒体和NADPH预孵育时,观察到Km/Ki比值显著增加(分别增至8.8、3.9、0.62和13)。因此,NOR的酶促氧化增强了其对P450活性的抑制能力。实际上,改变后的Km/Ki比值表明,NOR生物转化为其代谢产物后,对睾酮羟基化的四条途径的抑制作用分别增加了17倍、6.6倍、2.5倍和47倍。从这些实验中可以明显看出,主要由P450 2C11催化的睾酮2α-和16α-羟基化受到的抑制增加最为显著。在这些条件下,微粒体P450的表观含量降低,因此提示形成了一种NOR代谢产物中间体(MI)与细胞色素的复合物。此外,对微粒体中以及包含纯化的P450 2C11的重组系统中NOR的NADPH支持的代谢进行的光吸收差异光谱分析表明,在454 nm附近出现了一个吸收峰,类似于三乙酰竹桃霉素、SKF 525-A和奥芬那君产生的吸收峰。微粒体中该吸收峰的形成被针对雄性特异性P450 2C11产生的抗体所抑制。由于NOR氧化代谢为抑制性产物不一定涉及MI复合物形成,因此进行了额外实验,在评估睾酮羟基化之前,通过Sep-Pak mini-C18柱去除微粒体孵育中产生的与NOR相关的游离代谢产物。该实验的主要发现是,在Sep-Pak柱上去除未结合的NOR代谢产物后,P450 3A2依赖性类固醇6β-羟化酶活性受到的抑制程度要小得多(Sep-Pak萃取后抑制率为25%,而在随后的睾酮羟基化过程中存在所有NOR代谢产物时观察到的抑制率为82%);Sep-Pak处理后,P450 2C11介导的2α-和16α-羟基化的抑制作用没有明显差异。(摘要截短至400字)